Zaltrap: new treatment option for metastatic colorectal cancer

Zaltrap (aflibercept) is licensed for the treatment of metastatic colorectal cancer that is resistant to or has progressed following oxaliplatin therapy, in combination with irinotecan, 5-FU and folinic acid (FOLFIRI).

 Zaltrap is administered by intravenous infusion over 1 hour every two weeks and is continued until disease progression or unacceptable toxicity
Zaltrap is administered by intravenous infusion over 1 hour every two weeks and is continued until disease progression or unacceptable toxicity

PHARMACOLOGY 

Aflibercept is a recombinant fusion protein that binds to vascular endothelial growth factor (VEGF) receptors 1 and 2. By binding to these receptors, it reduces the growth of blood vessels that supply tumours with oxygen and nutrients.1

CLINICAL STUDIES

Aflibercept was investigated in a randomised, double-blind trial in 1,226 patients with metastatic colorectal cancer who had previously received oxaliplatin therapy, with or without prior bevacizumab.2

The addition of aflibercept to FOLFIRI significantly improved median survival relative to placebo plus FOLFIRI, from 12.1 months to 13.5 months, respectively. The overall response rate in the aflibercept plus FOLFIRI arm was 19.8% versus 11.1% for placebo plus FOLFIRI (p=0.0001).2

 REFERENCES

  1. Zaltrap Summary of Product Characteristics, February 2013.
  2. Van Cutsem E et al. J Clin Oncol 2012; 30: 3499–506.

View Zaltrap drug record

Further information: Sanofi

Follow MIMS on Twitter

 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

A woman wearing a white vest as a blue-gloved hand of a healthcare professional are seen injecting a vaccine.

'Nocebo' effect may cause two-thirds of COVID-19 vaccine reactions, study suggests

Two-thirds of adverse reactions reported with the COVID-19...

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...